Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration

BACKGROUND: Aflibercept is widely used as a treatment for neovascular age-related macular degeneration (nAMD). Nevertheless, there is no consensus in the optimal injection frequency in the 2(nd) year of treatment along with little real-world data on visual outcomes. On that basis, the primary aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Siempis, Thomas, El Abiary, Mariam, Patel, Radhika, Gupta, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561052/
https://www.ncbi.nlm.nih.gov/pubmed/31198295
http://dx.doi.org/10.4103/ojo.OJO_24_2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561052/
https://www.ncbi.nlm.nih.gov/pubmed/31198295
http://dx.doi.org/10.4103/ojo.OJO_24_2018

Ejemplares similares